Prospective monitoring of cutaneous adverse drug reactions in a secondary care hospital, UAE


  • Fatma Al Mulla Department of Clinical Pharmacy and Pharmacology, RAKMHSU, Ras Al Khaimah, UAE
  • Sathvik B. Sridhar Department of Clinical Pharmacy and Pharmacology, RAKMHSU, Ras Al Khaimah, UAE
  • Ghada Abu Al Hassan Department of Dermatology, Umm AL Quwain Hospital, Umm Al Quwain, UAE
  • Atiqulla Sharif Department of Clinical Pharmacy and Pharmacology, RAKMHSU, Ras Al Khaimah, UAE



Cutaneous adverse drug reactions, Dermatology, Nonsteroidal anti-inflammatory drugs, Outpatients, Adverse drug reactions monitoring


Background: Adverse drug reactions (ADRs) are one of the most important causes of morbidity, hospitalization, increased healthcare cost and even mortality. Cutaneous adverse reactions are most commonly documented for drugs. The aim of the study was to monitor the incidence and nature of cutaneous adverse drug reactions (CADRs) in the dermatology outpatients and identify the causative drugs.

Methods: A prospective observational study was conducted at the dermatology outpatient department of a secondary care hospital, UAE. All the patients attending dermatology outpatient and satisfying the inclusion criteria were monitored for ADRs. The required data were collected from the patients, their case files, and caretakers and entered in a suitably designed ADR reporting and documentation form. The causality, severity, and preventability of cutaneous ADRs were assessed using Naranjo, WHO, Hartwig and modified Schumock and Thornton scale.

Results: The prevalence of cutaneous ADRs was found to be 2.6%. Majority (43.4%) of the cutaneous ADRs were caused by nonsteroidal anti-inflammatory drugs. Majority (56.5%) of the study population reported itching as the most common cutaneous ADR. Also, 60.8% of the reported ADRs were “probable” in nature according to World Health Organization scale, whereas 56.5% reports were “probable” according to Naranjo’s algorithm. Majority (97%) of the ADRs were not preventable.

Conclusions: Nonsteroidal anti-inflammatory drugs were the common causes of cutaneous ADRs in the study. Majority of the adverse reactions were mild in nature. The type and nature of cutaneous adverse drug reaction profile documented in this study is almost similar in many ways to other ADRs monitoring studies conducted in dermatology outpatient clinics.


Nerurkar RP, Nadkar MY, Bichile SK. Need for monitoring adverse drug reactions. J Assoc Physicians India. 1998;46:673-674.

Lazarou J, Pomeranz B, Corey P. Incidence of Adverse Drug Reactions in Hospitalized Patients. JAMA. 1998;279(15):1200.

Davies E, Green C, Taylor S, Williamson P, Mottram D, Pirmohamed M. Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes. PLoS One. 2009;4(2):e4439.

Diagnostic Approach in Allergic and Irritant Contact Dermatitis. Medscape. 2016. Available at: Accessed on 7th February 2016.

Patel TK, Thakkar SH, Sharma DC. Cutaneous adverse drug reactions in Indian population: A systematic review. Indian Dermatol Online J. 2014;5:76–86.

Lee A, Thomson J. Drug-induced skin reactions. In: Lee A, editor. Adverse Drug Reactions. 2nd ed. London, UK: Pharmaceutical Press; 2006: 126-155.

Chan A, Lee H, Ho C, Cham T, Lin S. Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study. Current Therap Res. 2008;69(2):118-29.

Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137:765-70.

De Groot A, Beverdam E, Ayong C, Coenraads P, Nater J. The role of contact allergy in the spectrum of adverse effects caused by cosmetics and toiletries. Contact Dermatitis. 1988;19(3):195-201.

Digiovanni C, Acoraci V, Gambardella L, Sautebin L. Cosmetovigilance survey: Are cosmetics considered safe by consumers? Pharmacological Res. 2006;53(1):16-21.

Al Raai F, Banodakar D, Epidemiological study of cutaneous adverse drug reactions in Oman. Oman Med J. 2008;23(1):21-7.

Jelvehgari M, Azimi H, Montazam H. Prevalence of Cutaneous Drug Eruption in Hospitalized Patients:A Report from Sina Hospital of Tabriz. Iranian J Dermatol. 2009;12 (1):16-9.

Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23(2):171-81.

Sushma M, Noel MV, Ritika MC, James J, Guido S. Cutaneous adverse cutaneous drug: a 9 year study from a South Indian Hospital. Pharmacoepidemiol Drug Saf. 2005;14(8):567–70.

Ganeva M, Gancheva T, Lazarova R, Tzvetanova Y, Hristakieva EA. Prospective study of adverse drug reactions in a dermatology department. Methods Find Exp Clin Pharmacol. 2007;29(2):107-12.

Wu X, Hu F, An D, Yan B, Jiang X, Kwan P, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav. 2010;19(3):405-8.

East-Innis AD, Thompson DS. Cutaneous drug reactions in patients admitted to the dermatology unit at the University Hospital of the West Indies, Kingston, Jamaica. West Indian Med J. 2009;58(3):227-30.

Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions. Am J Clin Dermatol. 2003;4:407–48.

Chia FL, Leong KP. Severe cutaneous adverse reactions to drugs. Curr Opin Int Med. 2007;6(5):448-453.

Campos-Fernandez MM, Ponce-De-Leon-Rosales S, Archer-Dubon C, Orozco-Topete R. Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit. Rev Invest Clin. 2005;57:770–4.

Edwards IR. The accelerating need for pharmacovigilance. J R Coll Physicians Lond. 2000;34(1):48-51.

Naranjo CA, Busto U, Sellars EM, Sandor P, Ruiz I, Roberts EA, et al. Method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Available at: Graphics/24734.pdf. Accessed on 2nd April 2016.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.

Mbuagbaw J, Mbuagbaw LE, Chiabi A, Bisseck C, Nkam M. Mucocutaneous adverse drug reactions. In:A Hospital Setting in Cameroon. Int J Dermat. 2007;6(2):1-6

Borch JE, Andersen KE, Bindslev-Jensen C. Cutaneous Adverse Drug Reactions Seen at a University Hospital Department of Dermatology. Acta Derm Venereol. 2006;86(6):523-7.

Chatterjee S, Ghosh A, Barbhuiya J, Dey S. Adverse cutaneous drug reactions:A one-year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol. 2006;38(6):429.

Hunziker T, Künzi U, Braunschweig S, Zehnder D, Hoigné R. Comprehensive hospital drug monitoring (CHDM):adverse skin reactions, a 20-year survey. Allergy. 1997;52(4):388-93.

Noel M V, Sushma M, Guido S. Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center. Indian J Pharmacol. 2004;36:292-5.

Atzori L, Pinna A, Mantovani L, Ferreli C, Pau M, Mulargia M, et al. Cutaneous adverse drug reactions to allopurinol: 10-year observational survey of the dermatology department - Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2011;26(11):1424-30.

Acharya T, Mehta D, Shah H, Dave J. Pharmacovigilance study of adverse cutaneous drug reactions in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2013;3(1):75.

Das N, Hazra A, Gharami R, Chowdhury S, Datta P, Saha A. Cutaneous adverse drug reaction profile in a tertiary care outpatient setting in Eastern India. Ind J Pharmacol. 2012;44(6):792.

Son Y, Lee J, Roh J. Causality assessment of cutaneous adverse drug reactions. Ann Dermatol. 2011;23(4):432.

Nandha R, Gupta A, Hashmi A. Cutaneous adverse drug reactions in a tertiary care teaching hospital: A North Indian perspective. Int J App Basic Med Res. 2011;1(1):50.

Verma R, Tiwari S, Gupta CM, Verma N. Cutaneous Adverse Drug Reactions-A Study of Clinical Patterns, Causality, Severity and Preventability. IOSRJDMS. 2014;13(7):102-9.

Dubey AK, Prabhu S, Shankar PR, Subish P, Prabhu MM, Mishra, et al. Dermatological adverse drug reactions due to systemic medications. A review of literature. J Pak Assoc Dermatol. 2006;16:28-38.

Sudershan V, Siddiqua S, Aruna D, Manmohan, Ramesh S, Nazia Y. Cutaneous adverse drug reactions in a tertiary care hospital. Der Pharmacia Lettre. 2011;3(6):210-7.

Sharma VK, Sethuraman G. and Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India. J Postgrad Med. 2001;47:95.

Acharya L, Rao P, Ghosh S. Study and evaluation of the various cutaneous adverse drug reactions in Kasturba hospital, Manipal. Ind J Pharm Sci. 2006;68(2):212.

Vijendra R, Pundarikaksha HP, Gopal MG, Girish K, Vasundara K, Jyothi R. A prospective study of cutaneous adverse drug reactions in a tertiary care hospital. Nat J Basic Med Sci. 2012;3(1):44- 51.

Neupane S, Sharma SR. Adverse Drug Reactions: A 6-Month Teaching Hospital Based Study from Mid-Western Nepal. J Clin Diagn Res. 2012;6(3):445-8.

Kasemsarn P, Kulthanan K, Tuchinda P, Dhana N, Jongjarearnprasert K. Cutaneous reactions to non-steroidal anti-inflammatory drugs. J Drugs Dermatol. 2011;10(10):1160-7.

Bharani KR, Chandel NR, Goyal CA. Dermatological Manifestations of Adverse Drug Reactions: An Observational Study from Tertiary Care Center of Central India. J Pharm Biomed Sci. 2014;04(03):208-14.

Acharya L, Rao P, Ghosh S. Study and evaluation of the various cutaneous adverse drug reactions in Kasturba hospital, Manipal. Ind J Pharm Sci. 2006;68(2):212.

Jamunarani R, Priya M. analysis of adverse drug reaction related hospital admissions and common challenges encountered in ADR reporting in a tertiary care teaching hospital. Asian J Pharm Clin Res. 2014;7(1):141-3.

Zaraa I, Jones M, Trojjet S, Cheikh Rouhou R, El Euch D, Mokni M, et al. Severe adverse cutaneous drug eruptions: epidemiological and clinical features. Int J Dermatol. 2011;50(7):877-80.






Original Research Articles